Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib for HIV-1 Reservoir Reduction
NCT07342491Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Arm 1: dasatinib with Arm 2: Placebo (2 arms). Primary endpoints: Change in intact HIV-1 reservoir size at 12 weeks and Number of Study treatment-related adverse events at 36 weeks. Started May 2026; status: recruiting.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07342491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342491.